XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 31.80

-0.1%

Nov 21 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: opalapril who wrote (6505)	6/21/1998 11:47:00 AM
From: Robert K.	Read Replies (1) of 17367

Opalapril>"poor neuprex trial results" I disagree. If results were so poor then how come FDA allowed a P3? Two points. 1. Trauma results indicated efficacy in lung 2. Overall results indicated efficacy if only "surgical site" is removed. IMO they are learning how to use it. IMO they will demonstrate this in the P3. In the meantime we have a sepsis trial (meningococcemia). Will results prove positive? I cant say. We have to wait and see. All discalimers always apply.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next